Abstract Our objective was to assess the effects of HIV infection and antiretroviral therapy on trabecular and cortical microarchitecture in postmenopausal minority women. A subgroup of 106 (46 HIV-infected, 60 uninfected) postmenopausal Hispanic and African American women from an established cohort had areal bone mineral density (aBMD) measured by dual-energy X-ray absorptiometry and trabecular and cortical volumetric BMD (vBMD) and microarchitecture measured by high-resolution peripheral quantitative computed tomography (HRpQCT) at the radius and tibia. HIV-infected women were slightly younger (58 ± 1 vs. 61 ± 1 years, p = 0.08), and had lower body mass index (BMI; 28 ± 1 vs. 32 ± 1 kg/m 2 , p \ 0.01). BMI-adjusted aBMD Z scores were lower in HIV-infected women at the lumbar spine, total hip, and ultradistal radius. Serum N-telopeptide and C-telopeptide levels were also higher in HIV-infected women. Trabecular and cortical vBMD were similar at the radius, but cortical area (105.5 ± 2.4 vs. 120.6 ± 2.0 mm 2 , p \ 0.01) and thickness (956 ± 33 vs. 1,075 ± 28 lm, p \ 0.01) at the tibia were approximately 11-12 % lower in HIV-infected women. Differences remained significant after adjusting for age, BMI, and race/ethnicity. In contrast, cortical porosity was similar in the two groups. Although HIV-infected postmenopausal women had lower aBMD at the spine, total hip, and ultradistal radius and higher levels of bone resorption markers, the only differences detected by HRpQCT were lower cortical thickness and area at the tibia.
Low bone mineral density (BMD) has been associated with HIV infection and its therapy [1] , and recent data suggest that fracture rates may be higher in HIV-infected individuals [2] [3] [4] . As HIV-infected individuals live longer with effective antiretroviral therapy (ART), age-related bone loss will be superimposed upon bone loss already sustained and related to HIV infection and its therapy.
In the United States, older minority women represent a growing segment of those living with HIV [5] . We have previously reported that areal BMD (aBMD) by dualenergy X-ray absorptiometry (DXA) is lower at the lumbar spine and hip and that bone turnover markers are higher in HIV-infected than uninfected postmenopausal Hispanic and African American women [6] . In contrast to younger women and men on established ART [7] [8] [9] [10] [11] , we also found that aBMD by DXA decreases more rapidly in HIVinfected women on established ART than in uninfected controls, particularly at the distal forearm [12] .
DXA is a powerful clinical tool for diagnosis of osteoporosis and prediction of fracture but estimates BMD based upon an areal projection rather than measuring true volumetric BMD (vBMD) and cannot distinguish between cortical and trabecular bone. High-resolution peripheral quantitative computed tomography (HRpQCT) is a noninvasive imaging technology that provides a three-dimensional (3D) measurement of true M. Y. has a consultant/advisory role to Abbott and Gilead. All other authors have stated that they have no conflict of interest.
vBMD at the distal radius and tibia and permits separate assessment of cortical and trabecular bone and trabecular microarchitecture [13, 14] . We have reported that measurement of vBMD and microarchitecture by HRpQCT discriminates fragility fracture status in premenopausal women with unexplained osteoporosis, postmenopausal women, and patients with chronic kidney disease [15] [16] [17] .
HIV-infected individuals are at higher risk of fracture than the general population [18, 19] , and we have reported lower aBMD in HIV-infected postmenopausal women [6] . We therefore performed HRpQCT scans in a subset of our original cohort, hypothesizing that HIV-infected women would have lower cortical and trabecular vBMD and greater microarchitectural deterioration than uninfected controls.
Methods

Study Subjects
Between 2002 and 2007, 187 (92 HIV-infected, 95 HIVuninfected) postmenopausal women were recruited from the infectious diseases and general internal medicine clinics at Columbia University Medical Center (CUMC) and the HIV clinic at Bronx-Lebanon Hospital Center (BLHC) in New York City into a longitudinal study. Our intention was to recruit HIV-uninfected controls similar to HIVinfected subjects with regard to other chronic medical illnesses and comorbidities [6] . Eligible subjects were over age 40, self-identified as Hispanic or African American race/ethnicity, and postmenopausal as defined by [1 year of amenorrhea. In addition to amenorrhea, serum folliclestimulating hormone had to be either [30 or [20 mIU/mL with a concomitant serum estradiol of\30 pg/mL. Women with metabolic bone disease, multiple myeloma, cancer, endocrinopathies, serum creatinine [1.5 mg/dL, celiac or inflammatory bowel disease, current glucocorticoid or anticonvulsant use, current hormone replacement therapy, and current or past treatment of osteoporosis were excluded. Characteristics of the cohort have been published previously [6, 12, 20] . We measured cortical and trabecular vBMD and microarchitecture by HRpQCT in an unselected subset of 46 HIV-infected and 60 HIV-uninfected postmenopausal women who were enrolled sequentially into the study after we acquired HRpQCT capability in 2006. These 106 subjects and their initial HRpQCT scans comprise the current analysis.
Medical, surgical, and reproductive history; osteoporosis risk factors; current and past medication history; and HIV and ART history were obtained by interview and chart review. For hysterectomized women, time since menopause was estimated as years since onset of menopausal symptoms; if none, menopausal age was set at 50. Control subjects met the same criteria; enzyme-linked immunosorbent assay (ELISA) testing verified HIV-uninfected status.
This study was approved by the institutional review boards of the CUMC and BLHC. All subjects provided written informed consent.
Bone Density Measurements BMD of the lumbar spine (LS; L1-L4), femoral neck (FN), total hip (TH), nondominant one-third distal radius (DR), ultradistal radius (UDR), and body composition were measured by DXA on a QDR 4500 bone densitometer (Hologic, Bedford, MA) at the CUMC. Short-term in vivo precision is 0.68 % for the LS, 1.36 % for the TH, and 0.70 % for the radius.
T scores, which compare subjects to the peak bone mass of young individuals of the same sex and race, were derived for the hip from the National Health and Nutrition Examination Survey or the manufacturer's normative database for the spine and forearm. Osteoporosis and osteopenia were defined by World Health Organization criteria for postmenopausal Caucasian women: T scores B-2.5 represent osteoporosis and T scores between -1.0 and -2.49 represent osteopenia [21] . Z scores, comparing BMD to an age-, sex-, and ethnicity-matched reference population, were also calculated. Height and weight were measured by Harpenden stadiometer and balance beam scale, respectively.
Cortical and Trabecular Microarchitectural Measurements
vBMD and microarchitecture were assessed at the nondominant DR and tibia using a single HRpQCT device (XtremeCT; Scanco Medical, Brüttisellen, Switzerland). This system allows for in vivo evaluation of bone at a nominal voxel size of 82 lm. The region of interest (ROI) at the radius consisted of an *9-mm length of bone located 9.5-18.5 mm proximal to the end plate. At the tibia, the ROI was located 22-31 mm proximal to the end plate [13, 22] . The volume of interest was automatically separated into cortical and trabecular regions using a gaussian filter and a threshold-based algorithm. Microarchitectural analysis was performed as previously described [13, [23] [24] [25] . The following parameters were reported: mean cortical thickness (Ct.Th, lm); cortical and trabecular bone density (Ct.vBMD and Tb.vBMD, mg HA/cm 3 ); and trabecular number (Tb.N, mm -1 ), thickness (?Tb.Th, lm), and separation (Tb.Sp, lm). The standard deviation of Tb.Sp (Tb.Sp.SD, lm) was also measured, to assess the heterogeneity of the trabecular network.
Extended cortical parameters were measured with a newer algorithm incorporated in the manufacturer's analysis software (lCT Evaluation v6.0, Scanco Medical) [26] [27] [28] . This automated cortical analysis was first based on a dualthreshold algorithm that permits segmentation of the dense cortical bone compartment and generates periosteal and endosteal contours that were visually validated. A second step consisted of segmentation of cortical porosity, where endosteal and periosteal voids, transcortical erosions, and objects with a volume \0.003 mm 3 (i.e., five connected voxels) were discarded. Finally, microarchitectural and density parameters were measured from the refined cortical ROI as the combination of segmented cortical bone compartment and cortical porosity. The outcome parameters were cortical vBMD (mg HA/cm 3 ) and tissue mineral density (Ct.TMD, mg HA/cm 3 ), which is the average mineral density within the cortical bone compartment after exclusion of all pore space and erosion of a two-voxel-thick layer on the periosteal and endosteal boundaries to minimize partial volume effects. Mean Ct.Th (lm) was measured by a direct 3D method [29] disregarding the presence of pores. Cortical porosity (Ct.Po, %) was calculated as the ratio of cortical pore volume (Ct.Po.V) over the cortical bone compartment volume. Mean and distribution (SD) of cortical pore diameter (respectively, Ct.Po.Dm and Ct.Po.Dm.SD, lm) were measured by a direct 3D method [29] .
Laboratory Methods
Fasting morning serum, stored at -80°C, was batchanalyzed in the CUMC research laboratory for parathyroid hormone [radioimmunoassay (RIA); Corning-Nichols Laboratory, San Clemente, CA], serum 25-hydroxyvitamin D (RIA; Diasorin, Stillwater, MN), bone-specific alkaline phosphatase (ELISA; Quidel, San Diego, CA), osteocalcin (RIA; Immutopics, San Clemente, CA), and cross-linked N-telopeptide of type I bone collagen (NTx, competitiveinhibition ELISA; Inverness Medical, Princeton, NJ). C-Telopeptide of type 1 collagen (CTx) was measured by sandwich ELISA (Serum Crosslaps; IDS, Fountain Hills, AZ). Tumor necrosis factor-a (TNF-a) was measured by ELISA (Quantikine; R&D Systems, Minneapolis, MN); interleukin-6 (IL-6) was measured by RIA (Diasorin). CD4 counts were measured by flow cytometry (FACS Calibur; Becton Dickinson, San Jose, CA).
Statistical Analysis
All analyses were performed using SAS (version 9.2; SAS Institute, Cary, NC). Continuous data are presented as mean ± SD; categorical data are presented as percentage or absolute number. To reduce the number of microarchitectural parameters to those that differed most between the HIVinfected and HIV-uninfected groups, means between groups were compared using Student's t-test. Covariate-adjusted means between groups were compared by analysis of covariance. Between-group differences in correlations between DXA and HRpQCT measures were tested with analysis of variance of homogeneity of slopes. Categorical data were compared by odds ratios from chi-squared, Fisher's exact, or Jonckheere-Terpstra test for trend. No adjustments were made for multiple comparisons during this data-reduction analysis, and tibial cortical area and thickness were identified for further analysis. p \ 0.05 was considered statistically significant.
Univariate associations of demographic, anthropometric, reproductive, medical, and lifestyle variables with tibial cortical thickness and area were examined. These variables entered a stepwise multiple regression (p of 0.20 to enter and 0.05 to be retained in the model, SAS Proc REG; SAS Institute) to identify variables independently related to cortical thickness and area. Collinearity was assessed, and model-selected nonoverlapping covariates were retained for inclusion in the final inferential models. The measures identified were subsequently entered into regression models to permit assessment of the independent contribution of HIV status to cortical thickness and area.
Results
Characteristics of the Study Population
HIV-infected women were slightly, although not significantly, younger than uninfected women but had similar age at menopause. HIV-infected women had lower weight and BMI and were more likely to be hepatitis C virus-infected compared to HIV-uninfected women (Table 1) . Fifty-four percent of HIV-infected women had a history of AIDS, 81 % were currently receiving ART, and mean CD4 count was 553 ± 52 cells/mm 3 . Among HIV-infected women on ART, 12 (26 %) were on nonnucleoside reverse transcriptase inhibitor (NNRTI)-containing regimens, 22 (48 %) were on protease inhibitor (PI)-containing regimens, and 11 (30 %) were on tenofovir.
There were no between-group differences in the prevalence of radiographic vertebral fractures or history of fracture at any site. HIV-infected women had higher levels of the bone resorption markers NTx and CTx, and there was a trend for higher levels of TNF-a in HIV ? women (p = 0.08); group differences in TNF-a reached statistical significance in the cross-sectional analysis of the full cohort [6] .
BMD by DXA HIV-infected women had significantly lower mean T scores at the LS, TH, FN, and UDR (Table 1) . After adjustment for age and BMI, absolute aBMD and T scores remained lower in HIV ? women at the UDR but were no longer significant at the LS, TH, and DR. HIV-infected women had lower mean Z scores at the LS, TH, FN, DR, and UDR (Table 1) ; Z scores remained lower in the HIV-infected group at the LS, TH, and UDR after adjustment for BMI.
Cortical and Trabecular Structure by HRpQCT
All HRpQCT measurements at the radius and most at the tibia were similar between the HIV-infected and uninfected women ( Table 2) . At the tibia, HIV-infected women had lower total vBMD, but the difference was not significant (p = 0.06). Only cortical area and thickness were significantly lower (by 11-12 %) in the HIV-infected women. With the extended algorithm method, which may include more trabecularized cortical bone from the endosteal surface of the cortex, tibial cortical area was approximately 8-10 % higher and cortical thickness approximately 15 % higher in both the HIV-infected and uninfected groups compared to the standard algorithm. With the extended algorithm, HIV-infected women also had 11-12 % lower tibial cortical area and thickness than HIV-uninfected women (Table 3 ). These differences remained significant after adjustment for age and BMI (p = 0.03 and p = 0.01, respectively). HRpQCT images from two representative HIV-infected and uninfected women of similar age illustrate the observed group difference in tibial cortical thickness (Fig. 1) .
We also assessed whether group differences in tibial cortical area and thickness were due to differences in cortical porosity (Table 3) . Cortical pore volume was lower in women likely reflects their lower cortical thickness (Table 3) .
Subgroup Analyses by Ethnicity and Fracture History
To explore whether race/ethnicity obscured differences by HIV status, we stratified the analysis by Hispanic and African American race/ethnicity. In both race/ethnicity groups, the same HRpQCT pattern emerged: HIV-infected women had lower tibial cortical area and cortical thickness than uninfected women, but all other parameters were similar (data not shown).
To examine whether any HRpQCT parameters were associated with fracture history in our cohort, we grouped all 106 women together (46 HIV-infected ? 60 HIVuninfected). Subjects reporting a history of fracture (n = 18) had similar HRpQCT measurements as subjects without a history of fracture (data not shown). Similarly, HRpQCT parameters did not differ in women with (n = 6) and without radiographic evidence of vertebral fracture.
Determinants of Cortical Thickness and Area at the Tibia
We used regression analysis to assess whether HIV status was an independent predictor of tibial cortical thickness and area after adjustment for potential confounders (Table 4 ). In the model for cortical thickness, greater number of years since menopause, diabetes, and HIV status were associated with lower thickness, while higher BMI was associated with greater thickness. In the model for cortical area, greater number of years since menopause, diabetes, and HIV status were associated with lower area, while higher BMI and being Hispanic were associated with higher area. HIV status remained a significant predictor in the multivariate cortical area model, while in the cortical thickness model HIV status did not reach statistical significance (p = 0.06). 
ART and HRpQCT Parameters
HRpQCT parameters did not differ in HIV-infected women on (n = 37) and off (n = 9) ART. HRpQCT parameters also did not differ between groups on PI-, NNRTI-, or tenofovir-containing regimens. However, when we examined the correlations between cumulative use or class of ART and HRpQCT parameters, we found a modest positive correlation between cumulative PI use and radial total (r = 0.339, p = 0.02) and trabecular (r = 0.306, p = 0.04) area as well as tibial total (r = 0.321, p = 0.03) and trabecular (r = 0.306, p = 0.04) area. In contrast, there was a negative correlation between cumulative tenofovir use and radial trabecular vBMD (r = -0.286, p = 0.056) and trabecular number (r = -0.343, p = 0.02) and a positive association with radial trabecular separation (r = 0.507, p = 0.0004) and heterogeneity of separation (r = 0.496, p = 0.0005). There were no significant correlations with cumulative NNRTI use and HRpQCT parameters.
Conclusions
HIV-infected women had lower age-and BMI-adjusted aBMD by DXA (Z scores) than postmenopausal uninfected women at central skeletal sites (LS, TH) and the UDR. In contrast, HIV-infected and uninfected women did not differ with regard to cortical and trabecular vBMD or trabecular microarchitecture at the DR or trabecular parameters at the tibia. At the tibia, cortical area and cortical thickness, estimated by both standard and extended algorithms, were 11-12 % lower in HIV-infected women, while cortical porosity did not differ. Adjustment for age and BMI attenuated group differences for aBMD at all sites except the UDR, suggesting that lower body weight contributed to the differences in aBMD at the spine and hip. However, tibial cortical area and thickness remained lower in HIVinfected women after adjustment for age and BMI in both African American and Hispanic women, suggesting that the differences in cortical microarchitecture were independent of age and weight. It is noteworthy that aBMD by DXA was lower but vBMD at the tibia and radius by HRpQCT did not differ between HIV-infected and uninfected women. Even at the UDR, where the sites measured by DXA and HRpQCT are closely aligned though not identical, HIV-infected women had lower aBMD by DXA but no discernible differences in either total, cortical, or trabecular vBMD by HRpQCT. These results suggest that DXA may overestimate group differences in BMD in these women. As cross-sectional area (bone size) was similar between the groups, we cannot attribute this overestimation to smaller bone size in the HIV-infected women. It is also possible that the discrepancy we observed could be related to measurement site, at least in part, as HRpQCT assesses only the peripheral skeleton. As yet, there are no other HRpQCT studies of HIV-infected individuals with which to compare our results. Of two published studies that utilized both DXA and central QCT to assess spine and hip aBMD and vBMD in HIV-infected and uninfected individuals, one found congruent results [30] and the other found discrepant results [31] by the two methodologies. Additional studies using both central and peripheral QCT are necessary to clarify the discrepancy between measurements of areal and vBMD in these women.
The finding that HIV-infected women had similar crosssectional area but lower cortical area and thinner cortices suggests that endocortical resorption may have been higher in HIV-infected women. This finding is characteristic of bone loss in late menopause, a time when accelerated endocortical resorption that is not balanced by periosteal apposition results in accelerated loss concentrated in cortical bone [32] . These results support the hypothesis that bone loss in HIV-infected postmenopausal women is predominantly related to an augmentation of the endosteal remodeling associated with estrogen deficiency. As trabecular loss is typical of late perimenopause and early postmenopause [33] , comparable amounts of trabecular loss may have already occurred in both groups. Since our study was cross-sectional and we compared the groups at one point later in menopause (mean years since menopause of 9-12 years), we cannot determine whether rate of trabecular loss was comparable or higher in HIV-infected women.
In HIV-infected women, HRpQCT parameters did not differ among ART groups, although there were modest associations with cumulative PI or tenofovir exposure. The observed negative association between cumulative tenofovir use and trabecular parameters suggests that exposure to tenofovir may result in greater microarchitectural deterioration. This is consistent with many studies demonstrating decreased aBMD by DXA with tenofovir exposure in the setting of antiretroviral initiation [34, 35] , switch [36] , or utilization as preexposure prophylaxis in HIV-uninfected individuals [37] . Larger, longitudinal studies are necessary to define the acute and chronic impact of specific antiretrovirals on vBMD and microarchitecture.
Recent studies suggest that fracture incidence is higher in HIV-infected individuals, particularly older men and women, than population controls, even after adjustment for important predictors of fracture such as age, race/ethnicity, BMI, and comorbidities [18, 19] . However, it is uncertain whether an isolated finding of lower cortical thickness at the tibia in HIV-infected women would ultimately contribute to higher fracture risk, particularly when vBMD is not different. Other HRpQCT studies in HIV-uninfected individuals with and without fracture have reported differences in cortical thickness ranging 12-33 % [13, [38] [39] [40] [41] . The cortical differences we report are clearly at the low end of this range, and moreover, those studies also found differences in other cortical or trabecular parameters that we did not find in our study [16, 24, 42, 43] . In addition, HRpQCT assesses the peripheral skeleton, and isolated lower tibial cortical thickness may have no bearing on risk for the most clinically important fractures of the central skeleton, the spine and hip. The higher fracture rates reported in HIV-infected postmenopausal women may be due to higher bone remodeling, a risk factor for fracture that is independent of BMD, or to nonskeletal risks, such as increased falls among older HIV-infected individuals. It is also possible that the bone microstructure of individuals of African American and Hispanic race/ethnicity differs from that of Caucasians and Asians, who constitute the bulk of studies examining microarchitecture in women with and without fractures.
To our knowledge, this is the first study to use HRpQCT to examine bone microarchitecture in HIV-infected individuals. A major strength of our study is that the control group was similar in age and race/ethnicity and the participants were well characterized. However, there are several limitations to our study. There were group differences in weight and BMI among African American women, requiring adjustment for these differences in analyses. The study was not powered to detect group differences in HRpQCT parameters in HIV-infected women by current ART regimen or by immunologic criteria such as CD4 or history of AIDS. We were not able to evaluate the central skeleton, where most important fractures occur. There were too few women with fractures to assess whether there were differences in DXA or HRpQCT parameters by fracture status. The large number of statistical tests performed raises the possibility that the differences in cortical area and thickness at the tibia were due to chance alone, although the fact that HIV status remained a significant predictor of cortical area and a near-significant predictor of cortical thickness in the multivariate model suggests that the relationship is valid.
In conclusion, HIV-infected, minority, late postmenopausal women have lower aBMD by DXA at the hip and UDR and 11-12 % lower tibial cortical area and thickness but no differences in trabecular or cortical vBMD or trabecular microarchitecture of the DR and tibia by HRpQCT. While the clinical significance of this isolated finding, with regard to fracture risk, is uncertain, our results are somewhat reassuring. Larger studies using central QCT and including fractured and nonfractured individuals are necessary to elucidate the microarchitectural characteristics of increased bone fragility in HIV infection.
